JP2020529970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529970A5 JP2020529970A5 JP2019572373A JP2019572373A JP2020529970A5 JP 2020529970 A5 JP2020529970 A5 JP 2020529970A5 JP 2019572373 A JP2019572373 A JP 2019572373A JP 2019572373 A JP2019572373 A JP 2019572373A JP 2020529970 A5 JP2020529970 A5 JP 2020529970A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- domain
- ubiquitin
- car according
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102000044159 Ubiquitin Human genes 0.000 claims description 16
- 108090000848 Ubiquitin Proteins 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 16
- 230000002519 immonomodulatory effect Effects 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 6
- 102100032783 Protein cereblon Human genes 0.000 claims description 6
- 230000004068 intracellular signaling Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 108020001756 ligand binding domains Proteins 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 150000003949 imides Chemical class 0.000 claims description 3
- 229960004942 lenalidomide Drugs 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000688 pomalidomide Drugs 0.000 claims description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
- 229960003433 thalidomide Drugs 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000011748 cell maturation Effects 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1710620.4A GB201710620D0 (en) | 2017-07-03 | 2017-07-03 | Targeted protein degradation |
| GB1710620.4 | 2017-07-03 | ||
| PCT/EP2018/067741 WO2019007869A1 (en) | 2017-07-03 | 2018-07-02 | TARGETED DEGRADATION OF PROTEINS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529970A JP2020529970A (ja) | 2020-10-15 |
| JP2020529970A5 true JP2020529970A5 (enExample) | 2021-07-26 |
| JP7369039B2 JP7369039B2 (ja) | 2023-10-25 |
Family
ID=59592357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572373A Active JP7369039B2 (ja) | 2017-07-03 | 2018-07-02 | 標的化タンパク質分解 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10683360B2 (enExample) |
| EP (1) | EP3649149A1 (enExample) |
| JP (1) | JP7369039B2 (enExample) |
| CN (1) | CN110997710A (enExample) |
| BR (1) | BR112019028024A2 (enExample) |
| CA (1) | CA3068365A1 (enExample) |
| GB (2) | GB201710620D0 (enExample) |
| WO (1) | WO2019007869A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2018085208A1 (en) | 2016-11-02 | 2018-05-11 | The Research Foundation For The State University Of New York | Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction |
| CN111107874A (zh) * | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| BR112020007576A2 (pt) * | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
| US12049482B2 (en) * | 2017-10-31 | 2024-07-30 | The Brigham And Women's Hospital, Inc. | Molecular switch-mediated control of engineered cells |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| EP3908329A4 (en) * | 2019-01-07 | 2022-12-07 | The Regents of the University of California | CAGE DEGRON-BASED MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USE THERE |
| KR20210112347A (ko) * | 2019-01-07 | 2021-09-14 | 유니버시티 오브 워싱턴 | 단백질 분해의 조정 가능한 제어를 위한 단백질 스위치의 데노보 설계 |
| CN111825769B (zh) * | 2019-04-16 | 2022-03-25 | 上海科技大学 | 一种泛素化缺失的嵌合抗原受体及其用途 |
| US20220251152A1 (en) * | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| AU2020391285B2 (en) * | 2019-11-27 | 2024-05-23 | Onegene Biotechnology Inc. | Multifunctional multispecific multimeric biomolecule polymer having prolonged in-vivo duration |
| US20230114854A1 (en) * | 2020-02-14 | 2023-04-13 | Cellgentek Co., Ltd. | Chimeric antigen receptor targeting b-cell maturation antigen and use thereof |
| CN114057890A (zh) * | 2020-07-31 | 2022-02-18 | 南京北恒生物科技有限公司 | 新型共刺激结构域及其用途 |
| CN116368152A (zh) * | 2020-09-13 | 2023-06-30 | 山东博安生物技术股份有限公司 | 通过受体tac技术的膜结合蛋白的下调 |
| CN112266404A (zh) * | 2020-10-28 | 2021-01-26 | 北京大学深圳研究生院 | 选择性修饰靶标蛋白的基团转移方法及其应用 |
| CN112940096A (zh) * | 2021-01-29 | 2021-06-11 | 西安交通大学 | 一种膀胱癌血清多肽标志物及其应用 |
| IL304904A (en) * | 2021-02-01 | 2023-10-01 | St Phi Therapeutics Co Ltd | Target protein degradation system and its use |
| CN112980882A (zh) * | 2021-03-15 | 2021-06-18 | 上海科技大学 | Crbn基因在构建GSPT1敏感模型中的用途 |
| NL2031325B1 (en) | 2022-03-18 | 2023-09-29 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Novel zinc finger degron sequences |
| JP2025539386A (ja) | 2022-12-01 | 2025-12-05 | エー・テー・ハー・チューリッヒ | 修飾アミノ酸デグロン（ｍａａｄ）を同定する方法 |
| WO2025248464A2 (en) | 2024-05-29 | 2025-12-04 | Cell Control Biotherapeutics, Inc. | Loop reinforcement expression system for improved cell therapy products |
| CN119699269B (zh) * | 2024-07-10 | 2025-10-17 | 太原市中心医院 | 基于sbsn 600位赖氨酸发生二羟基异丁酰化修饰的用于银屑病研究的小鼠模型构建方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1417344B1 (en) * | 2001-08-17 | 2011-06-15 | Toolgen, Inc. | Zinc finger domain libraries |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
| EP2818480B1 (en) * | 2012-02-24 | 2020-08-26 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same |
| CN103265635A (zh) * | 2013-04-28 | 2013-08-28 | 中山大学附属第一医院 | 一种通用的靶向蛋白嵌合型分子化合物的构建方法 |
| KR20250127179A (ko) * | 2014-04-14 | 2025-08-26 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| US20170306385A1 (en) * | 2014-10-10 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Methods for discovering therapeutics that alter the stability of target proteins |
| EP3331905B1 (en) * | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| EP3347712B1 (en) * | 2015-09-11 | 2022-05-11 | The Broad Institute, Inc. | Methods of identifying drug-modulated polypeptide targets for degradation |
| US10830762B2 (en) * | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| ES2916335T3 (es) * | 2016-10-20 | 2022-06-30 | Celgene Corp | Receptores de antígeno quimérico heterodimerizable basados en cereblon |
-
2017
- 2017-07-03 GB GBGB1710620.4A patent/GB201710620D0/en not_active Ceased
-
2018
- 2018-07-02 CA CA3068365A patent/CA3068365A1/en active Pending
- 2018-07-02 WO PCT/EP2018/067741 patent/WO2019007869A1/en not_active Ceased
- 2018-07-02 EP EP18735571.4A patent/EP3649149A1/en not_active Withdrawn
- 2018-07-02 BR BR112019028024-3A patent/BR112019028024A2/pt not_active Application Discontinuation
- 2018-07-02 CN CN201880057133.9A patent/CN110997710A/zh active Pending
- 2018-07-02 JP JP2019572373A patent/JP7369039B2/ja active Active
- 2018-07-02 GB GB1810814.2A patent/GB2568987A/en not_active Withdrawn
- 2018-07-02 US US16/024,999 patent/US10683360B2/en active Active
-
2020
- 2020-05-21 US US16/879,896 patent/US11427643B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529970A5 (enExample) | ||
| Mazinani et al. | CAR-T cell potency: from structural elements to vector backbone components | |
| US11472884B2 (en) | Humanized BCMA antibody and BCMA-CAR-T cells | |
| JP2022062001A (ja) | 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート | |
| JP2020010699A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| RU2018109426A (ru) | Химерные антигенные рецепторы со встроенными контролируемыми функциями | |
| JP2018525006A5 (enExample) | ||
| FI3823665T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| IL277398B1 (en) | Pd-l1 binding affimers, and uses related thereto | |
| US20210015870A1 (en) | Bcma-car-t cells | |
| CA3176552A1 (en) | Immune activating fc domain binding molecules | |
| JP2017524367A5 (enExample) | ||
| CA3087149A1 (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
| JP2020514375A5 (enExample) | ||
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| AU2015315199A1 (en) | Chimeric receptors and uses thereof in immune therapy | |
| IL311608A (en) | Preparations and methods for the selective elimination and replacement of hematopoietic stem cells | |
| JP2018535701A5 (enExample) | ||
| RU2020109577A (ru) | Клетка | |
| JP2023138962A (ja) | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 | |
| WO2019087151A1 (en) | Cd38-directed chimeric antigen receptor constructs | |
| JP2025517479A (ja) | Ｂｃｍａ－ｃｄ１９を標的とする二重特異性キメラ抗原受容体およびその用途 | |
| CN113045657A (zh) | 一种人源化抗人bcma单克隆抗体及其car-t细胞 | |
| CA3154389A1 (en) | Antigen recognizing receptors targeting cd371 and uses thereof |